- Home
- GXAI vs CANF Comparison
GXAI vs CANF Comparison
Compare GXAI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | CANF |
|---|---|---|
| Founded | 2021 | 1994 |
| Country | United States | Israel |
| Employees | 3 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 4.9M |
| IPO Year | 2022 | 2011 |
Fundamental Metrics
Financial Performance| Metric | GXAI | CANF |
|---|---|---|
| Price | $0.40 | $1.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 119.5K | 27.5K |
| Earning Date | 11-20-2026 | 09-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,933,030.00 | N/A |
| Revenue This Year | $462.16 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 47901.74 | N/A |
| 52 Week Low | $0.41 | $0.17 |
| 52 Week High | $5.26 | $10.40 |
Technical Indicators
Market Signals| Indicator | GXAI | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 31.61 |
| Support Level | N/A | N/A |
| Resistance Level | $0.52 | $2.27 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 27.02 | 33.00 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.